NCT06696755View on ClinicalTrials.gov

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

February 5, 2026

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Bipolar I DisorderBipolar II Disorder
Interventions
DRUG

Icalcaprant

Oral Capsules

DRUG

Placebo for Icalcaprant

Oral Capsules

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY